Skip to content
Sign In Subscribe
Reuters — Companies — Pharmaceuticals — Health — Corporate Structure — Mergers & Acquisitions

Bayer plans to spend $1 bln on US pharma R&D in 2023-US pharma head

Bayer AG plans to spend $1 billion on drug research and development in the U.S. this year. They have raised the number of U.S. employees working on marketing for its pharmaceutical business by around 50%, and plan to expand it by another 75% by 2030.

1 min read
  • Bayer plans to spend $1 billion on drug research and development in the U.S. this year.
  • Bayer has raised the number of U.S. employees working on marketing for its pharmaceutical business by around 50% over the last three years, and plans to expand on that by another 75% by 2030.
  • Bayer plans to sell the drugs it is developing itself in the U.S., rather than partner with U.S. companies.
Bayer plans to spend $1 bln on US pharma R&D in 2023-US pharma head
Bayer AG plans to spend $1 billion on drug research and development in the U.S. this year as it works to double its sales in the country by the end of the decade, Bayer's top U.S. pharmaceutical executive told Reuters.
Reuters

More in Pharmaceuticals

More in Companies

More from Reuters

Latest